Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Achieve Life Sciences (ACHV) Long-Term Debt Issuances (2016 - 2017)

Achieve Life Sciences (ACHV) has disclosed Long-Term Debt Issuances for 2 consecutive years, with $20000.0 as the latest value for Q1 2017.

Quarterly Long-Term Debt Issuances changed N/A to $20000.0 in Q1 2017 from the year-ago period, while the trailing twelve-month figure was $70000.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $9.8 million for FY2024, N/A changed from the prior year.
Long-Term Debt Issuances for Q1 2017 was $20000.0 at Achieve Life Sciences, down from $50000.0 in the prior quarter.
The five-year high for Long-Term Debt Issuances was $50000.0 in Q4 2016, with the low at $20000.0 in Q1 2017.